Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
NCT00020774 · Jonsson Comprehensive Cancer Center · PHASE2 · withdrawn · last registry update 2020-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Jonsson Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-06-18Phase 3 first posted: Changhai Hospital, a drug against RRM1 (NCT04931394)
- 2021-06-11Phase 3 first posted: Janssen Research & Development, LLC, Bortezomib + Dexamethasone (NCT04923893)
- 2020-11-16Phase 3 first posted: National Cancer Institute (NCI), Cisplatin + Doxorubicin Hydrochloride (NCT04628767)
- 2020-10-08Phase 3 first posted: National Cancer Institute (NCI), Docetaxel + Eribulin Mesylate (NCT04579224)
- 2020-10-05Phase 3 first posted: University Health Network, Toronto, Gemcitabine + Cisplatin (NCT04574960)
- 2020-09-22Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Cisplatin + Gemcitabine Hydrochloride (NCT04559139)
- 2020-02-13Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04267848)
- 2019-12-02Phase 3 first posted: Janssen Research & Development, LLC, Cilta-cel + Pomalidomide (NCT04181827)
- 2019-10-04Phase 3 first posted: University of Birmingham, Ruxolitinib + Hydroxycarbamide (NCT04116502)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision